Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly to allow more patients to apply for special access to unapproved obesity drug" is generating significant coverage in the Business category, with 11 articles from 10 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Houston Chronicle, MDLinx, STAT and RAPS. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 48d ago.
Quick answers
Why is "Eli Lilly to allow more patients to apply for special access to unapproved obesi" trending?
Because 10 independent news sources published 11 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies? Houston Chronicle · 52d ago
- Retatrutide access expands, putting physicians on the front line of ‘next-gen’ GLP-1 demand MDLinx · 52d ago
- Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more STAT · 52d ago
- Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca RAPS · 52d ago
- Eli Lilly expanding early access to retatrutide weight loss drug qz.com · 52d ago
- Three biotechs with three news updates statnews.com · 52d ago
- This Next-Gen GLP-1 Is Blowing Up the Black Market Economy Marie Claire · 52d ago
- Retta Weight Loss: The Evidence, Benefits, and Realistic Expectations FC Bayern · 52d ago
- Spotlight On: Good news and bad news for Lilly's triple agonist FirstWord Pharma · 52d ago
- Eli Lilly to offer early access to next-gen obesity drug to some patients reuters.com · 52d ago
- Eli Lilly to allow more patients to apply for special access to unapproved obesity drug STAT · 52d ago
Topics
Related trends
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Another post-Eli Manning nightmare for Giants and their fans as Jaxson Dart feared done for season
3 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.